This week we have four IPOs up for grabs in what will be your last chance to participate in an IPO for the month of July. If you waited, you missed some good performance last week as four IPO's that launched averaged a 21% return, and spent more time in the media then any other week this year. Of course this is all helped due to the fact that major indices have been climbing to, and holding near record highs. When you take a close look at the IPO pipeline you will see a well-stocked list of names in line. This leads most analysts to believe that there will see no shortage of IPO activity going forward.

First up is Talend (TLND  ), which is a company that provides a cloud-based data integration platform. The company plans to raise $84 million by offering 5.25 million shares at a range of $15-17. Though currently unprofitable, the company addresses a $16 billion market and has managed to secure big-name customers such as General Electric, Allianz and Citi. Analysts agree that the company may continue the trend of top-performing tech IPO's this year.

Bioventus (BIOV  ) plans to raise $150 million next week by issuing 8.8 million shares at a range of $16-18. The company specializes in orthobiologic products and has successfully supplemented its mature bone repair device and hyaluronic acid injection business with an acquired portfolio of higher-growth surgical products.

Kadmon (KDMN  ) is a biotech focused on developing kinase inhibitors for autoimmune and other diseases, is set to raise $100 million to fund further clinical trials of its Phase 2 lead candidate. Kadmon is looking to issue 5.5 million shares at a range of $16-20. You may be interested to know that the company was founded by former ImClone CEO Sam Waksal after his prison term for insider trading relating to the Marth Stewart scandal. The biotech is now led by brother Harlan Waksal and had an accumulated deficit of $677 million as of the most recent quarter. 

Finaly we have Kinsale (KNSL  ), which is led by former executives from James River (JRVR  ) which is up 62% since its IPO in December of last year. Kinsale is set to be the only public pure-play insurer in the excess and surplus industry. They hope to raise $90 million by issuing 6 million shares at a range of $14-16.Analysts seem to be focused on the fact that the company has maintained an industry-leading combined ratio, though its average premiums declined in the same period.